Aeterna's AEZS-108 final Phase 2 results in endometrial cancer to be presented at ESGO 2011

Download PDF Copy

Jul 19 2011

NewsGuard 100/100 Score

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that final Phase 2 results in endometrial cancer on its anticancer compound, AEZS-108, will be presented during a poster session at the upcoming 17^th International Meeting of the European Society of Gynaecological Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan Convention Center in Milan, Italy.

The trial was conducted by the German AGO Study Group and study centers in Bulgaria. AEZS-108, a targeted cytotoxic peptide conjugate, is currently in Phase 1/2 programs in prostate and bladder cancer, and has successfully completed Phase 2 trials in endometrial and ovarian cancer.

Source:

AETERNA ZENTARIS INC.

Posted in: Drug Trial News | Medical Condition News

Tags: Bladder, Bladder Cancer, Cancer, Chemotherapy, Compound, Doxorubicin, Endometrial Cancer, Multiple Myeloma, Myeloma, Oncology, Ovarian Cancer, Peptides, Prostate

Comments (0)

Download PDF Copy

Suggested Reading

Air pollution linked to head and neck cancer risk

Air pollution linked to head and neck cancer risk

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

New vaccine shows potential in preventing recurrence of triple-negative breast cancer

Innovative urine test could improve pancreatic cancer survival rates

Innovative urine test could improve pancreatic cancer survival rates

AI-powered tool predicts gene activity in cancer cells from biopsy images

AI-powered tool predicts gene activity in cancer cells from biopsy images

Researchers uncover key genes linked to DCIS progression

Researchers uncover key genes linked to DCIS progression

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Scientists map cancer mutations in EGFR gene, revealing drug resistance paths

Advances in bladder cancer treatments offer hope for curative care

Advances in bladder cancer treatments offer hope for curative care

Study shows AI can predict prognosis in triple-negative breast cancer

Study shows AI can predict prognosis in triple-negative breast cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

How different types of bread impact cancer risk